Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver, which can progress rapidly and has a poor prognosis. Glypican-3 (GPC3) has been proposed to be an important diagnostic biomarker and therapeutic target for HCC. Aptamers have emerged as promising drug delivery vehicles becaus...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jun Young, Chae, Ju Ri, Cho, Ye Lim, Kim, Youndong, Lee, Dasom, Lee, Jeong Kyun, Kang, Won Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588995/
https://www.ncbi.nlm.nih.gov/pubmed/33080969
http://dx.doi.org/10.3390/pharmaceutics12100985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588995/
https://www.ncbi.nlm.nih.gov/pubmed/33080969
http://dx.doi.org/10.3390/pharmaceutics12100985

Ejemplares similares